Nautilus Biotechnology, Inc. 8K

Nautilus Biotechnology, Inc. entered into a $125 million at-the-market common stock sales agreement with TD Securities (USA) LLC.

On September 11, 2026, Nautilus Biotechnology, Inc. entered into a Sales Agreement with TD Securities (USA) LLC (doing business as TD Cowen) establishing an at-the-market equity offering program under which Nautilus may, from time to time and at its sole discretion, issue and sell up to an aggregate of $125,000,000 of its common stock through TD Cowen as sales agent and/or principal, pursuant to an effective Form S-3 shelf registration statement and related ATM prospectus supplement, with specified procedures for placement notices, trade execution, settlement, commissions, and customary representations, warranties and covenants regarding the company and the offering.

Filing Facts

CIK

1808805

Ticker

-

Form

8K

Source Type

sec

Accession

0001808805-26-000041

Alert Tier

6